Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGLENASDAQ:AMRNNASDAQ:NVCTNASDAQ:TERN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGLEAeglea BioTherapeutics$11.47$2.66▼$32.75$48.64M2.5795,409 shs43,300 shsAMRNAmarin$9.11-2.7%$9.78$7.08▼$20.60$187.07M1.3872,691 shs115,140 shsNVCTNuvectis Pharma$8.86+1.8%$8.19$4.44▼$11.80$207.25M-0.11121,777 shs125,600 shsTERNTerns Pharmaceuticals$2.41+7.4%$3.15$1.87▼$11.40$209.95M-0.131.51 million shs891,657 shs7 Top Nuclear Stocks To Buy NowNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGLEAeglea BioTherapeutics0.00%0.00%0.00%0.00%0.00%AMRNAmarin0.00%-2.04%-0.98%-18.37%-50.33%NVCTNuvectis Pharma0.00%+6.62%-1.12%+61.38%+31.07%TERNTerns Pharmaceuticals0.00%+12.38%-23.89%-45.71%-47.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAMRNAmarin0.2462 of 5 stars1.02.00.00.02.20.00.0NVCTNuvectis Pharma2.0744 of 5 stars3.50.00.00.00.65.00.6TERNTerns Pharmaceuticals4.1528 of 5 stars3.32.00.04.13.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGLEAeglea BioTherapeutics 0.00N/AN/AN/AAMRNAmarin 2.00Hold$7.00-23.16% DownsideNVCTNuvectis Pharma 3.00Buy$15.6776.82% UpsideTERNTerns Pharmaceuticals 2.60Moderate Buy$18.38664.03% UpsideCurrent Analyst Ratings BreakdownLatest AGLE, AMRN, NVCT, and TERN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2025AMRNAmarinThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$20.00 ➝ $7.004/2/2025NVCTNuvectis PharmaMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$17.003/21/2025TERNTerns PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform3/17/2025NVCTNuvectis PharmaLaidlawSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.002/28/2025TERNTerns PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform2/25/2025NVCTNuvectis PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $11.00(Data available from 4/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGLEAeglea BioTherapeutics$2.33M0.00N/AN/A($60.61) per share0.00AMRNAmarin$228.61M0.82N/AN/A$1.35 per share6.75NVCTNuvectis PharmaN/AN/AN/AN/A$0.70 per shareN/ATERNTerns PharmaceuticalsN/AN/AN/AN/A$4.13 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGLEAeglea BioTherapeutics-$83.82M-$75.59N/AN/AN/A-22,195.36%-132.05%-146.87%N/AAMRNAmarin-$59.11M-$4.00N/AN/AN/A-16.33%-7.22%-4.96%5/7/2025 (Estimated)NVCTNuvectis Pharma-$22.26M-$1.11N/AN/AN/AN/A-155.80%-104.02%5/6/2025 (Estimated)TERNTerns Pharmaceuticals-$90.21M-$1.13N/AN/AN/AN/A-32.76%-31.33%5/12/2025 (Estimated)Latest AGLE, AMRN, NVCT, and TERN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025TERNTerns Pharmaceuticals-$0.29N/AN/AN/AN/AN/A5/7/2025Q1 2025AMRNAmarin-$0.06N/AN/AN/AN/AN/A5/6/2025Q1 2025NVCTNuvectis Pharma-$0.30N/AN/AN/AN/AN/A3/20/2025Q4 2024TERNTerns Pharmaceuticals-$0.30-$0.24+$0.06-$0.24N/AN/A3/12/2025Q4 2024AMRNAmarin-$1.20-$2.40-$1.20-$0.12$32.37 million$62.31 million3/4/2025Q4 2024NVCTNuvectis Pharma-$0.28-$0.36-$0.08-$0.36N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/AAMRNAmarinN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGLEAeglea BioTherapeuticsN/A4.594.59AMRNAmarinN/A3.232.11NVCTNuvectis PharmaN/A2.742.74TERNTerns PharmaceuticalsN/A32.9932.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGLEAeglea BioTherapeuticsN/AAMRNAmarin22.25%NVCTNuvectis Pharma96.77%TERNTerns Pharmaceuticals98.26%Insider OwnershipCompanyInsider OwnershipAGLEAeglea BioTherapeutics6.60%AMRNAmarin1.96%NVCTNuvectis Pharma35.78%TERNTerns Pharmaceuticals15.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGLEAeglea BioTherapeutics694.05 million3.78 millionOptionableAMRNAmarin36020.53 million402.62 millionOptionableNVCTNuvectis Pharma823.39 million12.41 millionNot OptionableTERNTerns Pharmaceuticals4087.30 million72.11 millionNot OptionableAGLE, AMRN, NVCT, and TERN HeadlinesRecent News About These CompaniesRussell Investments Group Ltd. Decreases Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)April 19 at 3:33 AM | marketbeat.comAlliancebernstein L.P. Has $2.01 Million Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)April 19 at 3:15 AM | marketbeat.comLilly touts results for once-daily weight-loss and antidiabetic pillApril 18 at 11:25 PM | cen.acs.orgVanguard Group Inc. Has $21.44 Million Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)April 17 at 3:10 AM | marketbeat.comExodusPoint Capital Management LP Lowers Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)April 16 at 3:37 AM | marketbeat.comViking Rises as Pfizer’s Oral Obesity Med FaltersApril 14, 2025 | biospace.comNorges Bank Acquires New Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)April 12, 2025 | marketbeat.comPolymer Capital Management HK LTD Increases Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)April 9, 2025 | marketbeat.comTerns Pharmaceuticals management to meet with OppenheimerApril 8, 2025 | markets.businessinsider.comDown -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a TurnaroundApril 7, 2025 | zacks.comDown -31.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Terns Pharmaceuticals (TERN)April 3, 2025 | zacks.comTerns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)April 2, 2025 | globenewswire.comAll You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to BuyMarch 26, 2025 | zacks.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMarch 25, 2025 | marketbeat.comOppenheimer Remains a Buy on Terns Pharmaceuticals (TERN)March 25, 2025 | markets.businessinsider.comWilliam Blair Reaffirms Market Perform Rating for Terns Pharmaceuticals (NASDAQ:TERN)March 22, 2025 | marketbeat.comWilliam Blair Reaffirms Their Hold Rating on Terns Pharmaceuticals (TERN)March 22, 2025 | markets.businessinsider.comTerns Pharmaceuticals Reports 2024 Progress and OutlookMarch 22, 2025 | tipranks.comTerns Pharmaceuticals (NASDAQ:TERN) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPSMarch 21, 2025 | marketbeat.comWhy Terns Pharmaceuticals, Inc.’s (TERN) Stock Is Up 14.97%March 21, 2025 | aaii.comTerns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate UpdatesMarch 20, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAGLE, AMRN, NVCT, and TERN Company DescriptionsAeglea BioTherapeutics NASDAQ:AGLEAeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.Amarin NASDAQ:AMRN$9.11 -0.25 (-2.67%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$9.38 +0.27 (+2.96%) As of 04/17/2025 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Nuvectis Pharma NASDAQ:NVCT$8.86 +0.16 (+1.89%) As of 04/17/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.Terns Pharmaceuticals NASDAQ:TERN$2.40 +0.17 (+7.37%) Closing price 04/17/2025 03:59 PM EasternExtended Trading$2.48 +0.08 (+3.33%) As of 04/17/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation Unveils NYC Network Ahead of Key Earnings Report Joby Aviation Stock Presents an Opportunity in the Turbulence Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Tariff-Resistant Kinder Morgan Is a Good Buy in 2025 Rocket Lab's Growth Potential Gains Altitude on Defense News Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks Tariff-Resistant Abbott Laboratories on Track for New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
